Our activity is principally based on the development and optimization of Antibody-Drug Conjugates. Thanks to our patented conjugation technology and our expertise in monoclonal antibody development, we can help you develop your own medicine candidate.

Our main objective is to be part of the common effort in immuno-oncology research area to bring better cancer treatments to the clinic. We strongly believe that ADCs have a major role to play in combination with chemotherapues of tomorrow, along with cell therapies and immune response modulators.

We all have our own university background and experience, we have all worked in different activity sectors, but today we share the same implication for our project and work for the same objective. Meet the team behind Mablink Bioscience.